• 25-Oct-2011: NVS reports 3Q11 sales of generic Lovenox, which forms the basis for MNTA’s 45% profit share.
• 4-Feb-2013 (not a typo): Start of NVS/MNTA’s patent-infringement suit against Teva. (See #msg-61591240 for the relevance of this.)
Copaxone
• 7-Sep-2011: Copaxone patent trial begins on all arguments other than inequitable conduct. (The Judge may rule on the inequitable conduct argument that was litigated in a July 2011 mini-trial; however, the imminent start of the main trial makes this unlikely, IMO.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.